Most stem cell products look identical on a Certificate of Analysis. Cell counts, viability, sterility — all checked. None of it tells you whether the cells will actually perform when you inject them.
The difference between a clinically potent product and an expensive saline injection comes down to lab method — choices made in tissue isolation, culture environment, media composition, and preservation. Most suppliers don't want to discuss these choices because they made the cheap one. Here's how ATOM is different — and the questions every doctor should be asking every supplier they consider.
We don't enzymatically digest the umbilical cord. We don't mechanically shred it. We let the cells migrate naturally out of intact Wharton's jelly tissue — gradually, over time, in the presence of concentrated Wharton's jelly filtrate that recreates the cells' native biochemical environment.
The filtrate is patented. No other lab can legally produce or use it. It supplies the same extracellular matrix and niche signals the cells were already living in — which means they don't drift, don't stress, and don't lose the primitive markers that define a clinically potent MSC.
Every other supplier compromises here. We don't have to.
Take this list to your current supplier. See how they answer.
Market cells as "low passage" without disclosing population doublings. One passage can mean up to 10 doublings, depending on culture density. Passage 3 can equal PDL 30 — past the point where MSCs accumulate genetic drift, telomere shortening, and silent loss of function.
Every cord is tracked by Population Doubling Level (PDL), not just passage. We cap every product at PDL 18 or fewer. Once a line hits that threshold, we move to a new cord. No exceptions.
Why it matters: Cells that haven't aged out. Full multipotency intact. No silent loss of function masked by a "passage 2" label.
Grow cells in flat 2D culture flasks. It's cheap and scales easily. It also forces cells into an unnatural sheet geometry that alters gene expression and reduces potency compared to their native 3D environment.
3D bioreactor culture. Cells grow in three dimensions — the way they live in tissue. More technically demanding. More expensive at small scale. The only way to expand cells while preserving native phenotype.
Why it matters: Cells behave like cells, not flattened survivors of plastic. Higher potency per cell injected.
Use fetal bovine serum or, at best, human platelet lysate. Bovine serum coats cells in animal protein — which the recipient's immune system reads as foreign. Result: increased immunogenicity and inflammatory reactions on injection.
Fully defined, animal-product-free media. Zero non-human protein contamination. Cells grow in a chemically controlled environment with no foreign antigens to carry into the patient.
Why it matters: Lower immunogenicity. Cleaner clinical response. No surprise inflammatory reactions tied to the culture, not the patient.
Increasingly market peptide-based "wash-free" cryopreservation media — convenient, but typically derived from non-human sources (often fish proteins). Anything non-human is potentially immunogenic, and post-thaw viability is documented to be lower than DMSO.
DMSO-based cryopreservation — the documented gold standard for post-thaw cell viability. Yes, it requires a brief wash step before injection. The wash takes minutes. The viability advantage carries the entire treatment.
Why it matters: The cells you inject are alive. Period. We'll trade five minutes of prep for cells that actually engraft and signal.
Report "particle counts" measured by light scattering and label the result as exosomes. A particle count includes cellular debris, protein aggregates, and lipid fragments alongside true exosomes. Inflated numbers, real-world potency unknown.
True exosomes characterized by protein-marker verification — not particle scattering. The number on our label reflects therapeutic vesicles, not background noise.
Why it matters: You're paying for therapeutic exosomes. You should actually be receiving them.
Lyophilize (freeze-dry) exosomes for shelf-stable shipping. The freeze-drying process destroys the lipid bilayer that holds exosomal RNA. The RNA signaling — the actual mechanism of regenerative effect — is lost. What's left is a peptide cocktail with the word "exosomes" on the label.
Vitrification or frozen-state preservation. Lipid bilayers stay intact. RNA signaling is preserved. The exosome arrives at the clinic functional — peptides, RNA, and structure all delivered.
Why it matters: Full exosome biology in the syringe — not just the leftover peptides after the active machinery has been destroyed.